NUR 555 3-1 QUIZ QUESTIONS AND
CORRECT ANSWERS NEW UPDATE
2026-2027 SNHU
97 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Apply advanced pharmacokinetic and pharmacodynamic principles to predict drug interactions, adverse
effects, and therapeutic outcomes
2 Synthesize pathophysiologic mechanisms with pharmacologic interventions to develop safe,
evidence-based treatment plans
3 Evaluate clinical data and monitoring parameters to make timely, patient-centered prescribing decisions
4 Critically appraise current guidelines and landmark trials to justify therapeutic choices in complex
scenarios
5 NUR 555 3
6 1 Quiz Questions and Correct Answers New Update 2026
7 2027 SNHU
8 Foundations of Advanced Nursing Pharmacology, Pathophysiology, and Clinical Decision-Making
9 Applied Advanced Nursing Pharmacology, Pathophysiology, and Clinical Decision-Making
10 Advanced Advanced Nursing Pharmacology, Pathophysiology, and Clinical Decision-Making
11 Advanced Nursing Pharmacology, Pathophysiology, and Clinical Decision-Making Review
ABSTRACT
This study document brings together 97 carefully worded exam questions drawn from NUR 555 3-1
Quiz Questions and Correct Answers New Update 2026-2027 SNHU, with the strongest emphasis
placed on Apply advanced pharmacokinetic and pharmacodynamic principles to predict drug
interactions, adverse effects, and therapeutic outcomes, Synthesize pathophysiologic mechanisms
with pharmacologic interventions to develop safe, evidence-based treatment plans, Evaluate
clinical data and monitoring parameters to make timely and patient-centered prescribing decisions.
Every item follows the wording style and level of reasoning you meet in the real paper, and each
one is paired with a clear rationale so the correct choice is never a guess. Work through the set at
your own pace, mark the questions that slow you down, then come back to them until the
reasoning feels automatic. Learners who revise this way walk into the exam room recognising the
pattern behind the questions instead of meeting them for the first time. Keep going - steady, honest
practice is what turns a difficult paper into a comfortable pass.
Page 1
,Q1 APPLY ADVANCED PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO
PREDICT DRUG INTERACTIONS, ADVERSE EFFECTS, AND THERAPEUTIC OUTCOMES
A patient with heart failure and reduced ejection fraction (HFrEF) is started on
sacubitril/valsartan. Which concurrent medication requires immediate
discontinuation due to a high risk of angioedema?
A. Spironolactone
B. Lisinopril CORRECT
C. Metoprolol succinate
D. Dapagliflozin
RATIONALE: Sacubitril/valsartan is contraindicated with ACE inhibitors like lisinopril because
combined neprilysin and ACE inhibition markedly increases bradykinin levels, raising
angioedema risk. A 36-hour washout is required when switching. Spironolactone, metoprolol, and
dapagliflozin are safe and guideline-recommended companions in HFrEF.
Q2 APPLY ADVANCED PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO
PREDICT DRUG INTERACTIONS, ADVERSE EFFECTS, AND THERAPEUTIC OUTCOMES
Which cytochrome P450 enzyme is primarily responsible for the metabolism of
clopidogrel to its active metabolite, and what is the clinical implication for poor
metabolizers?
A. CYP3A4; poor metabolizers require higher doses.
B. CYP2C19; poor metabolizers have reduced antiplatelet effect and increased cardiovascular
risk. CORRECT
C. CYP2D6; poor metabolizers experience excessive bleeding.
D. CYP1A2; poor metabolizers need alternative antiplatelet therapy.
RATIONALE: Clopidogrel is a prodrug activated primarily by CYP2C19. Poor metabolizers (e.g.,
*2/*2 alleles) produce less active metabolite, leading to diminished platelet inhibition and higher
rates of stent thrombosis. CYP3A4, CYP2D6, and CYP1A2 play minor roles and are not the
primary determinants of response.
Page 2
,Q3 APPLY ADVANCED PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO
PREDICT DRUG INTERACTIONS, ADVERSE EFFECTS, AND THERAPEUTIC OUTCOMES
A patient on warfarin for atrial fibrillation is prescribed
trimethoprim-sulfamethoxazole for a urinary tract infection. Which monitoring
parameter is most critical to assess within 3-5 days?
A. Serum creatinine and potassium
B. INR and signs of bleeding CORRECT
C. Complete blood count with differential
D. Liver function tests
RATIONALE: Trimethoprim-sulfamethoxazole inhibits CYP2C9, which metabolizes warfarin, and
also displaces warfarin from albumin, markedly increasing INR and bleeding risk. Close INR
monitoring and dose adjustment are essential. While renal function and CBC are relevant, the
immediate life-threatening risk is hemorrhage from supratherapeutic anticoagulation.
Q4 APPLY ADVANCED PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO
PREDICT DRUG INTERACTIONS, ADVERSE EFFECTS, AND THERAPEUTIC OUTCOMES
Which pathophysiologic mechanism best explains the development of diabetic
ketoacidosis (DKA) in a patient with type 1 diabetes who is nonadherent with
insulin?
A. Excessive glucose uptake by cells leading to hypoglycemia.
B. Absolute insulin deficiency causing unrestrained lipolysis and ketogenesis. CORRECT
C. Increased counterregulatory hormone suppression of glucagon.
D. Enhanced peripheral insulin sensitivity.
RATIONALE: In type 1 diabetes, absolute insulin deficiency leads to unchecked lipolysis,
producing free fatty acids that are converted to ketone bodies in the liver, causing metabolic
acidosis. Counterregulatory hormones (glucagon, cortisol, catecholamines) are elevated, not
suppressed, and insulin sensitivity is not enhanced. Hypoglycemia is not a feature of DKA.
Page 3
, Q5 APPLY ADVANCED PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO
PREDICT DRUG INTERACTIONS, ADVERSE EFFECTS, AND THERAPEUTIC OUTCOMES
A patient with major depressive disorder has not responded to adequate trials of
two SSRIs. Which class of antidepressants is most appropriate to consider next
according to current STAR*D-informed guidelines?
A. Monoamine oxidase inhibitors (MAOIs)
B. Tricyclic antidepressants (TCAs)
C. Serotonin-norepinephrine reuptake inhibitors (SNRIs) CORRECT
D. Atypical antipsychotics as monotherapy
RATIONALE: After two failed SSRI trials, guidelines recommend switching to a different class,
such as an SNRI (e.g., venlafaxine, duloxetine), which has a distinct mechanism and favorable
safety profile. MAOIs and TCAs are generally reserved for later lines due to dietary restrictions
and toxicity. Atypical antipsychotics are typically used as adjuncts, not monotherapy, in this
context.
Q6 APPLY ADVANCED PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO
PREDICT DRUG INTERACTIONS, ADVERSE EFFECTS, AND THERAPEUTIC OUTCOMES
Which of the following best describes the mechanism by which SGLT2 inhibitors
reduce cardiovascular mortality in patients with heart failure?
A. Direct inhibition of myocardial sodium channels.
B. Natriuresis and reduction in preload and afterload. CORRECT
C. Stimulation of beta-adrenergic receptors.
D. Blockade of aldosterone receptors.
RATIONALE: SGLT2 inhibitors promote glycosuria and natriuresis, leading to reduced preload
and afterload, improved myocardial energetics, and decreased cardiovascular death and heart
failure hospitalizations. They do not directly inhibit myocardial sodium channels, stimulate beta
receptors, or block aldosterone receptors; those are mechanisms of other drug classes.
Page 4
CORRECT ANSWERS NEW UPDATE
2026-2027 SNHU
97 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Apply advanced pharmacokinetic and pharmacodynamic principles to predict drug interactions, adverse
effects, and therapeutic outcomes
2 Synthesize pathophysiologic mechanisms with pharmacologic interventions to develop safe,
evidence-based treatment plans
3 Evaluate clinical data and monitoring parameters to make timely, patient-centered prescribing decisions
4 Critically appraise current guidelines and landmark trials to justify therapeutic choices in complex
scenarios
5 NUR 555 3
6 1 Quiz Questions and Correct Answers New Update 2026
7 2027 SNHU
8 Foundations of Advanced Nursing Pharmacology, Pathophysiology, and Clinical Decision-Making
9 Applied Advanced Nursing Pharmacology, Pathophysiology, and Clinical Decision-Making
10 Advanced Advanced Nursing Pharmacology, Pathophysiology, and Clinical Decision-Making
11 Advanced Nursing Pharmacology, Pathophysiology, and Clinical Decision-Making Review
ABSTRACT
This study document brings together 97 carefully worded exam questions drawn from NUR 555 3-1
Quiz Questions and Correct Answers New Update 2026-2027 SNHU, with the strongest emphasis
placed on Apply advanced pharmacokinetic and pharmacodynamic principles to predict drug
interactions, adverse effects, and therapeutic outcomes, Synthesize pathophysiologic mechanisms
with pharmacologic interventions to develop safe, evidence-based treatment plans, Evaluate
clinical data and monitoring parameters to make timely and patient-centered prescribing decisions.
Every item follows the wording style and level of reasoning you meet in the real paper, and each
one is paired with a clear rationale so the correct choice is never a guess. Work through the set at
your own pace, mark the questions that slow you down, then come back to them until the
reasoning feels automatic. Learners who revise this way walk into the exam room recognising the
pattern behind the questions instead of meeting them for the first time. Keep going - steady, honest
practice is what turns a difficult paper into a comfortable pass.
Page 1
,Q1 APPLY ADVANCED PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO
PREDICT DRUG INTERACTIONS, ADVERSE EFFECTS, AND THERAPEUTIC OUTCOMES
A patient with heart failure and reduced ejection fraction (HFrEF) is started on
sacubitril/valsartan. Which concurrent medication requires immediate
discontinuation due to a high risk of angioedema?
A. Spironolactone
B. Lisinopril CORRECT
C. Metoprolol succinate
D. Dapagliflozin
RATIONALE: Sacubitril/valsartan is contraindicated with ACE inhibitors like lisinopril because
combined neprilysin and ACE inhibition markedly increases bradykinin levels, raising
angioedema risk. A 36-hour washout is required when switching. Spironolactone, metoprolol, and
dapagliflozin are safe and guideline-recommended companions in HFrEF.
Q2 APPLY ADVANCED PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO
PREDICT DRUG INTERACTIONS, ADVERSE EFFECTS, AND THERAPEUTIC OUTCOMES
Which cytochrome P450 enzyme is primarily responsible for the metabolism of
clopidogrel to its active metabolite, and what is the clinical implication for poor
metabolizers?
A. CYP3A4; poor metabolizers require higher doses.
B. CYP2C19; poor metabolizers have reduced antiplatelet effect and increased cardiovascular
risk. CORRECT
C. CYP2D6; poor metabolizers experience excessive bleeding.
D. CYP1A2; poor metabolizers need alternative antiplatelet therapy.
RATIONALE: Clopidogrel is a prodrug activated primarily by CYP2C19. Poor metabolizers (e.g.,
*2/*2 alleles) produce less active metabolite, leading to diminished platelet inhibition and higher
rates of stent thrombosis. CYP3A4, CYP2D6, and CYP1A2 play minor roles and are not the
primary determinants of response.
Page 2
,Q3 APPLY ADVANCED PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO
PREDICT DRUG INTERACTIONS, ADVERSE EFFECTS, AND THERAPEUTIC OUTCOMES
A patient on warfarin for atrial fibrillation is prescribed
trimethoprim-sulfamethoxazole for a urinary tract infection. Which monitoring
parameter is most critical to assess within 3-5 days?
A. Serum creatinine and potassium
B. INR and signs of bleeding CORRECT
C. Complete blood count with differential
D. Liver function tests
RATIONALE: Trimethoprim-sulfamethoxazole inhibits CYP2C9, which metabolizes warfarin, and
also displaces warfarin from albumin, markedly increasing INR and bleeding risk. Close INR
monitoring and dose adjustment are essential. While renal function and CBC are relevant, the
immediate life-threatening risk is hemorrhage from supratherapeutic anticoagulation.
Q4 APPLY ADVANCED PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO
PREDICT DRUG INTERACTIONS, ADVERSE EFFECTS, AND THERAPEUTIC OUTCOMES
Which pathophysiologic mechanism best explains the development of diabetic
ketoacidosis (DKA) in a patient with type 1 diabetes who is nonadherent with
insulin?
A. Excessive glucose uptake by cells leading to hypoglycemia.
B. Absolute insulin deficiency causing unrestrained lipolysis and ketogenesis. CORRECT
C. Increased counterregulatory hormone suppression of glucagon.
D. Enhanced peripheral insulin sensitivity.
RATIONALE: In type 1 diabetes, absolute insulin deficiency leads to unchecked lipolysis,
producing free fatty acids that are converted to ketone bodies in the liver, causing metabolic
acidosis. Counterregulatory hormones (glucagon, cortisol, catecholamines) are elevated, not
suppressed, and insulin sensitivity is not enhanced. Hypoglycemia is not a feature of DKA.
Page 3
, Q5 APPLY ADVANCED PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO
PREDICT DRUG INTERACTIONS, ADVERSE EFFECTS, AND THERAPEUTIC OUTCOMES
A patient with major depressive disorder has not responded to adequate trials of
two SSRIs. Which class of antidepressants is most appropriate to consider next
according to current STAR*D-informed guidelines?
A. Monoamine oxidase inhibitors (MAOIs)
B. Tricyclic antidepressants (TCAs)
C. Serotonin-norepinephrine reuptake inhibitors (SNRIs) CORRECT
D. Atypical antipsychotics as monotherapy
RATIONALE: After two failed SSRI trials, guidelines recommend switching to a different class,
such as an SNRI (e.g., venlafaxine, duloxetine), which has a distinct mechanism and favorable
safety profile. MAOIs and TCAs are generally reserved for later lines due to dietary restrictions
and toxicity. Atypical antipsychotics are typically used as adjuncts, not monotherapy, in this
context.
Q6 APPLY ADVANCED PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO
PREDICT DRUG INTERACTIONS, ADVERSE EFFECTS, AND THERAPEUTIC OUTCOMES
Which of the following best describes the mechanism by which SGLT2 inhibitors
reduce cardiovascular mortality in patients with heart failure?
A. Direct inhibition of myocardial sodium channels.
B. Natriuresis and reduction in preload and afterload. CORRECT
C. Stimulation of beta-adrenergic receptors.
D. Blockade of aldosterone receptors.
RATIONALE: SGLT2 inhibitors promote glycosuria and natriuresis, leading to reduced preload
and afterload, improved myocardial energetics, and decreased cardiovascular death and heart
failure hospitalizations. They do not directly inhibit myocardial sodium channels, stimulate beta
receptors, or block aldosterone receptors; those are mechanisms of other drug classes.
Page 4
